Bronchopulmonary neuroendocrine tumors

Area of Science:

• Pulmonology
• Oncology
• Pathology

Background:

• Bronchopulmonary neuroendocrine tumors (BP-NETs) constitute about 20% of lung cancers, originating from neuroendocrine cells.
• BP-NETs are classified into typical carcinoid (TC), atypical carcinoid (AC), large-cell neuroendocrine carcinoma (LCNEC), and small-cell lung carcinoma (SCLC), each with distinct biological behaviors.
• While sharing some features, these subtypes differ significantly in clinical presentation, prognosis, and treatment response.

Purpose of the Study:

• To provide a comprehensive overview of bronchopulmonary neuroendocrine tumors.
• To discuss the evolution, general characteristics, and current diagnostic and therapeutic options for BP-NETs.
• To highlight the varying prognoses and clinical behaviors among different BP-NET subtypes.

Main Methods:

• Literature review of bronchopulmonary neuroendocrine tumors.
• Analysis of epidemiological data, clinical presentations, and pathological features.
• Synthesis of current diagnostic modalities and therapeutic approaches.

Main Results:

• BP-NETs present with varied symptoms, including cough and hemoptysis; hormonal symptoms are rare (<5%).
• Small-cell lung carcinoma (SCLC) and large-cell neuroendocrine carcinoma (LCNEC) are aggressive with poor prognoses, while typical carcinoid (TC) and atypical carcinoid (AC) have better survival rates.
• Incidence of BP-carcinoids has increased, with limited curative treatment options beyond surgery, which is often not feasible.

Conclusions:

• Bronchopulmonary neuroendocrine tumors represent a heterogeneous group of lung neoplasms requiring subtype-specific management.
• Early diagnosis and tailored therapeutic strategies are crucial for improving outcomes in patients with BP-NETs.
• Further research is needed to address the increasing incidence and limited curative options for certain BP-NET subtypes.